Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of ECSP034842ApublicationCriticalpatent/ECSP034842A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
La invención se refiere a nuevos derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo[2,3-d]pirimidina, a procesos para su preparación, a su aplicación en un proceso para el tratamiento del cuerpo humano o animal, al uso de los mismos - solos o en combinación con uno o más compuestos farmacéuticamente activos diferentes - para el tratamiento de una enfermedad, en especial una enfermedad proliferativa, tal como una enfermedad tumoral, a un método para el tratamiento de estas enfermedades en mamíferos, en especial en seres humanos, y al uso de este compuesto - solo o en combinación con uno o más compuestos farmacéuticamente activos diferentes - para la preparación de una composición farmacéutica (medicamento) para el tratamiento en especial de una enfermedad proliferativa, tal como un tumor.The invention relates to new derivatives of 4-amino-5-phenyl-7-cyclobutyl-pyrrolo [2,3-d] pyrimidine, to processes for their preparation, to their application in a process for the treatment of the human or animal body , to the use thereof - alone or in combination with one or more different pharmaceutically active compounds - for the treatment of a disease, especially a proliferative disease, such as a tumor disease, to a method for the treatment of these diseases in mammals , especially in humans, and the use of this compound - alone or in combination with one or more different pharmaceutically active compounds - for the preparation of a pharmaceutical composition (medicament) for the special treatment of a proliferative disease, such as a tumor.
ECSP0348422001-05-142003-11-11
DERIVATIVES OF 4-AMINO-5-PHENYL-7-CYCLLOBUTIL-PIRROLO [2,3-D] PYRIMIDINE
ECSP034842A
(en)
Compounds derived from 2,3-dihydro-5h- [1,3] thiazolo [3,2-a] pyrimidin-5-one, modulators of pi3k; pharmaceutical composition; and use to treat an immune-based disease, cancer, or lung disease in a patient.
COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS
Methods of treating, controlling or preventing specific cancer and disease associated with unwanted angiogenesis and reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy, or immunotherapy in a patient. suffering from a specific cancer, pharmaceutical composition and kit
A PHARMACEUTICAL COMPOSITION SPONTANEALLY AVAILABLE FOR ORAL ADMINISTRATION, USE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER, METHOD FOR INCREASING BIODISPONIBILITY LEVELS OR REDUCING ITS VARIABILITY
Compounds derived from 7-fluoro-5-methyl-2- (phenylamino) -6,7,8,9-tetrahydro-5h-pyrimido [4,5-b] [1,4] diazepin-6 (7h) -one ; pharmaceutical composition comprising said compounds; and its use in the treatment of cancers, inflammation, alopecia, autoimmune, cardiovascular, infectious, nephrological, neurodfegenerative, skin and bone diseases.
Methods for treating benign prostatic hypertrophy, reducing a symptom associated with it, reducing prostate size in a human subject, and for bhp prophylaxis, oral unit dose pharmaceutical composition, and use of lonidamine or a lonidamine analogue
USE OF A TAXANE DERIVATIVE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, USE OF A BIODICABILITY IMPROVEMENT AGENT OF SUCH A DERIVATIVE ORAL DOSAGE FORM AND UNDERSTANDING ITEM AND METHOD FOR FORMING A BIO-AVAILABLE ACTIVE AGENT.